LGND

MKT CAP:$5B

Ligand Pharmaceuticals Incorporated

Market Cap

$5B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$237.75+$47.64 (+25.06%)

Jun 8, 2026

52W High $241.7952W Low $109.48

Company Details

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; ...

CEO

—

IPO Date

Nov 18, 1992

Website

www.ligand.com

Key Metrics TTM

Revenue

$274M

+51.2% YoY

Net Income

$154M

EPS (Diluted)

Free Cash Flow

$123M

Revenue / Share

$13.80

Gross Margin

98.6%

Operating Margin

36.7%

Net Margin

55.9%

FCF Margin

44.8%

P/S

16.8x

P/E

30.0x

Earnings Reports

Q2 2026

Aug 6, 2026

PENDING

Q1 2026

May 8, 2026

$52M+14.1%

FY 2025

Feb 27, 2026

$268M+60.4%

Q4 2025

Feb 27, 2026

$60M+39.4%

Q3 2025

Nov 7, 2025

$115M+122.8%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee